Company Overview and News
Sinclair Broadcast Group, the largest local television operator in the United States, tried to placate federal regulators on Wednesday regarding its proposal to buy a rival TV group. But the Federal Communications Commission still voted unanimously to have a judge review aspects of the deal, a potentially ominous sign for the merger.
TRBNW NYTAB SBGI TRCO TRBAB
In recent news, Alphabet Inc. (GOOGL - Free Report) was hit by a record-breaking $5 billion fine by EU regulators for breaking antitrust laws. According to The New York Times, this steep antitrust penalty is among one of the most aggressive regulatory moves ever made against an American technology company. The fine comes from Google abusing its Android market dominance in three different areas. The three areas outlined include Google bundling its search engine and Chrome apps into the operating system; blocking phone makers from creating devices that run forked versions of Android; and paying large manufacturers to bundle the Google search app on handsets, according to The Verge.
FB SAP SAPGF GOOGL MSFT NYTAB GOOG INTC
Get the DealBook newsletter to make sense of major business and policy headlines — and the power-brokers who shape them.
If a running shoe made you 25 percent faster, would it be fair to wear it in a race? What about 10 percent? Or 2 percent? The Nike Zoom Vaporfly 4% — a bouncy, expensive shoe released to the public one year ago — raises these questions like no shoe in recent distance running history.
American adults are having fewer kids—or foregoing parenthood entirely. A new survey conducted by Morning Consult for The New York Times sheds light on the dynamics behind the trend.
Get the DealBook newsletter to make sense of major business and policy headlines — and the power-brokers who shape them. __________
Ask ten Comcast (NASDAQ:CMCSA) shareholders if they really wanted the company to get into a bidding war with Walt Disney (NYSE:DIS) for most of Twenty-First Century Fox (NASDAQ:FOXA), and you’ll get ten different answers. By and large though, a common and unspoken response to Comcast’s probably bowing out of the race for Fox is “whew… expensive bullet dodged.”
FOX T CMCSA TWX NFLX NYTAB TWC FOXA DIS
Former United States President Barack Obama believes that ballooning wealth inequality is a threat to society, and that those who have the means should help those who are less fortunate.
The tech billionaire Elon Musk on Wednesday walked back his baseless claim that a British diver involved in the cave rescue efforts in Thailand was a pedophile, an accusation made after the man criticized a submarine that Mr. Musk had said he built to help with the rescue.
Over the past several years, cybersecurity has emerged as one of the hottest themes in the broader technology sector. Data suggest it could also be one of the most durable technology investment themes over the long-term.
STT STT.PRC STT.PRE XKFS STT.PRD STT.PRG DTEC CSCO NYTAB AIQ CIBR
His enemies paint him as all-powerful, but the billionaire philanthropist believes that his political legacy has never been in greater jeopardy.
LOS ANGELES—It’s been almost 30 years since Meg Ryan’s unforgettable orgasm scene in “When Harry Met Sally.” So when we recently interviewed that movie’s director, Rob Reiner, we pounced on the chance to talk to him about its milestone next year.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET